Chapter VII of the EU MDR focuses on post-market surveillance, vigilance, and market surveillance. Specifically, Article 83 of the EU MDR outlines the PMS System requirements. At a high level, manufacturers are required to "plan, establish, document, implement, maintain and update a post-market surveillance system in a manner that is proportionate to the risk class and appropriate for the type of device."
The PMS System is required to actively and systematically record and review data to analyze the safety, performance, and quality of the device throughout its lifetime.
The gathered data should be used to update:
and identify
and, when relevant,
The PMS System is part of the technical documentation of the device. Safety and performance benchmarks may be identified in the PMS Plan or CER for the device under evaluation and its similar devices or competitors in the scope of review.
The PMS Plan requirements are outlined in Article 84 of the EU MDR and references articles 83 - 86, Annex II, and Annex III. The PMS Plan must include a strategy for all requirements outlined in Article 83: Post Market Surveillance System (see above), in addition to the following:
The PMS Plan is often submitted as part of the technical documentation for Regulatory Body review, and in recent times, reviewed by these agencies more frequently and with more scrutiny than in years past.
The PMSR and PSUR are authored in an identical manner and made available to the Notified Body to ensure compliance with the EU MDR. These documents include the results of the information outlined in the PMS Plan and updated on a pre-defined cadence (as described in the chart below).PSURs for Implantable and Class III devices and above must be uploaded to EUDAMED. The PSUR will not be publicly visible to all EUDAMED users.
As per the EU MDR, the primary goals of the PSUR are to highlight:
Annexes can be added to the PSUR to meet the reporting requirements of other regions (such as Canada or Australia) rather than creating additional reports for those regions.
The Summary of Safety and Clinical Performance (SSCP) is a publicly accessible document that provides a clear, comprehensive overview of a medical device’s safety and clinical performance. Required under the EU MDR, the SSCP is designed to enhance transparency by offering healthcare professionals and patients essential information about the device, including its intended use, clinical benefits, potential risks, and the outcomes of clinical evaluations. This summary ensures that all stakeholders have access to critical data, supporting informed decision-making and promoting patient safety.
The PMS System is intended to include ongoing monitoring of data collected by the manufacturer and public resources. While the manufacturer collects complaint data, maintaining the collection of data from public sources remains a burden to post-market assurance teams. As part of this service, we offer monthly and quarterly reviews of the following databases to ensure you are aware of your device's and competitor's market standing. These reports are delivered every month with a quarterly and annual wrap-up. Adverse events and recall databases include:
Literature databases include:
Clinical Trial databases include:
R = Required
NR = Not Required
RA = Required Annually
R* = Required for implantable Devices
MedTech Writing and Consulting
Copyright © 2024 MedTech Writing and Consulting - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
..and let us handle your ongoing Post-Market Surveillance. See how your device (and similar devices) are operating out in the market!